Healthcare >> Analyst Interviews >> March 15, 2019
CRISPR and NASH Will Be Particularly Interesting and Exciting in 2019
Steven Seedhouse, Ph.D., is Vice President, Equity Research, Biotechnology at Raymond James Financial, Inc. Dr. Seedhouse has been a biotech equity research analyst or an associate at various firms since 2015. He joined Raymond James in March 2018. Prior to his career in equity research, Dr. Seedhouse completed a Ph.D. in pharmacology from Roswell Park Cancer Institute in Buffalo, New York, and holds an M.S. in medicinal chemistry from SUNY Buffalo. Profile
Word count: 3,701
TWST: Tell us what you cover and your thoughts on how this area was affected in 2018.
Dr. Seedhouse: Right now, we cover 14 companies total,